Kenneth H. Rand, MD
Kenneth H. Rand, MD, is a professor of pathology and medicine at the University of Florida College of Medicine.
1964: BA, biology, cum laude, Harvard College, Cambridge, Massachusetts
1969: MD, Stanford University, School of Medicine, Stanford, Calif.
1969 - 70: Intern in medicine, Stanford University, Stanford, Calif.
1970 - 71: First-year resident in medicine, Stanford University, Stanford, Calif.
1974 - 77: Fellowship, Division of Infectious Diseases, Stanford University, Stanford, Calif. (with Dr. Thomas C. Merigan), Stanford, Calif.
1976: Second-year resident in medicine, Stanford University Hospital (on leave of absence from Infectious Disease Fellowship) Stanford, Calif.
1. Deitchman AN, Singh RSP, Rand KH, Derendorf H. Enhanced in vitro activity of tigecycline in the presence of chelating agents. Int J Antimicrob Agents. 2018 Jan 3. pii: S0924-8579(17)30470-3. doi: 10.1016/j.ijantimicag.2017.12.027. [Epub ahead of print]29305959
2. Beal SG, Tremblay EE, Toffel S, Velez L, Rand KH., A Gastrointestinal PCR Panel Improves Clinical Management and Lowers Health Care Costs. Clin Microbiol. 2017 Dec 26;56(1). pii: e01457-17. doi: 10.1128/JCM.01457-17. Print 2018 Jan.PMID: 29093106
3. Rand KH, Beal SG, Lipori GP. Relationship between bacteriology report time in the morning and length of stay in hospital after the report. Diagn Microbiol Infect Dis. 2017 Nov;89(3):241-244. doi: 10.1016/j.diagmicrobio.2017.08.005. Epub 2017 Aug 12.PMID:28888673
4. Dickhaus, F., Hasan, M., Tremblay, E., Klinker, K., Rand, KH., Beal, SG Tobramycin Treatment on Cystic Fibrosis Patients with Pseudomonas aeruginosa. . Journal of Microbiology & Infectious Diseases. Dec2017, Vol. 7 Issue 4, p178-185.
Currently Involved In:
Clinical Microbiology: The research laboratory is focused on a project to use microarrays for viral discovery. Additionally, UF Health Pathology Laboratories actively studies the mechanism of synergy between daptomycin and rifampin against rifampin-resistant vancomycin-resistant E. faecium (VRE).
Sarcoidosis: A second major research focus is the search for an antigen or nucleic acid unique to sarcoidosis. Given the data using the Kveim antigen as a skin test for sarcoidosis, it seems inescapable that sarcoid tissue contains some antigenic component that is reasonably specific for the disease. Our approach involves purification of such an antigen and serological identification, as well as methods to identify associated nucleic acid.
Biotechnology Due Diligence: As start-up biotechnology companies search for venture capital to develop new technologies and products, due diligence is needed to provide an independent and objective assessment of their claims. UF Health Pathology Laboratories has the capability of evaluating both new technology and its biomedical applicability. Dr. Rand has more than 30 years of experience in basic biomedical research and patient care, as well as in the technical and medical/administrative direction of the UF Health Shands Hospital laboratory. Combining the breadth of this experience with the access to experts in all basic and clinical specialties at the University of Florida, UF Health Pathology Laboratories can provide a unique resource for the evaluation of new ideas, technologies or products.